Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **high affinity immunoglobulin epsilon receptor subunit gamma** (FcεRIγ) is an essential component of the tetrameric high-affinity IgE receptor complex (FcεRI), which consists of one alpha chain (IgE-binding), one beta chain (signal amplification), and two disulfide-linked gamma chains. The **gamma chains** contain immunoreceptor tyrosine-based activation motifs (*ITAMs*) that initiate intracellular signaling cascades upon antigen-induced crosslinking via bound IgE. This leads to rapid degranulation of mast cells or basophils—central events in immediate-type hypersensitivity reactions such as allergies. Beyond its role in allergy, **FcεRIγ** also serves as a common adapter/signaling module for other activating immune receptors including those recognizing other antibody classes (*e.g.*, certain FcγRs). It participates broadly in innate immunity through interactions with pattern recognition receptors on myeloid cells. Mutations or dysregulation can contribute to various pathologies involving abnormal inflammation or impaired host defense. The gene encoding this protein is *FCER1G*; it is expressed primarily on mast cells, basophils, eosinophils, Langerhans cells, some dendritic cell subsets—and inducibly elsewhere during inflammation. Its centrality makes it both a therapeutic target and a biomarker candidate for allergic diseases.
Drugs like omalizumab prevent crosslinking of FcεRI by neutralizing circulating IgE. This inhibits downstream signal transduction through the gamma subunits' ITAM motifs, blocking mast cell/basophil degranulation and release of inflammatory mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High affinity immunoglobulin epsilon receptor subunit gamma (FcεRIγ).